"The global bronchodilators market is predicted to grow at a 6.2% CAGR, from USD 28.3 billion in 2022 to USD 45.6 billion by 2031. Over the forecast period, North America is expected to lead the market."
The increasing prevalence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) worldwide is driving constant growth in the bronchodilator market. The growing need for bronchodilators is driven by factors such as smoking, an ageing population, and increased air pollution. Technological advancements in drug delivery technologies, as well as the development of combination therapies, are driving market expansion. Furthermore, the COVID-19 outbreak has improved respiratory health awareness, resulting in increased investment in novel bronchodilator therapy.
Changing market trend towards tailored medicines and personalised therapy for respiratory disorders
Targeted treatments for respiratory illnesses and customized therapy are clearly driving a trend in the bronchodilators market. Precision medical techniques, genetics, and biomarker studies all help to drive this change. Developing customized medicines targeted at certain biological pathways and patient subgroups is becoming more and more important for pharmaceutical businesses. In the development of biologics for severe asthma, where therapies are meant to target different inflammatory pathways depending on a patient's biomarketer profile, this tendency is especially clear.
Developing "smart" inhalers with sensors and digital technologies to track medication adherence and provide patients individualized feedback also attracts increasing attention. Eventually, this shift towards precision medicine in respiratory care is predicted to drive development in the bronchodilators market by improving treatment results, lowering side effects, and besting healthcare resources.
Growing rates of respiratory disorders and higher degrees of air pollution
Bronchodilators market is driven mostly by the rising frequency of respiratory illnesses, especially COPD and asthma. The World Health Organisation estimates that COPD affects around 251 million people worldwide whereas over 339 million people suffer from asthma worldwide. Rising air pollution levels, smoking behavior, and an aging population are among the many elements predicted to drive these figures up. Particularly air pollution has grown to be a major issue in many cities all around, aggravating respiratory problems and development of these disorders.
With a major share ascribed to respiratory ailments, the World Bank estimates that air pollution results in around 7 million yearly premature deaths. Effective bronchodilator drugs are thus in more and more demand to control these disorders and raise patients' quality of life. Further fueling the market expansion for bronchodilators, governments and healthcare institutions are also carrying awareness campaigns and efforts to fight respiratory illnesses.
Safety issues and side effects connected to long-term bronchodilator usage
Although bronchodilators are very helpful in controlling respiratory problems, their long-term usage raises safety questions and adverse effects concerns. Typical adverse effects of bronchodilators include tremor, fast heart rate, headaches, and sometimes more serious cardiovascular reactions. For example, long-acting beta-agonists (LABAs) have been linked to a higher risk of asthma-related mortality, which causes black box warnings from authorities. These safety issues may affect doctor writing practices and patient compliance, therefore restricting market expansion.
Furthermore under constant discussion is the proper use of various bronchodilators, especially in mild asthma patients; some studies indicate that misuse of short-acting beta-agonists (SABAs) may cause poor asthma control and more exacerbations. These elements have resulted in a more cautious approach to bronchodilator prescription and a drive for alternate therapeutic approaches, which could somewhat slow down market development. To solve these issues, nevertheless, constant research and development efforts are focused on creating novel formulations and combination treatments with better safety profiles.
Beta-2 agonists dominate the bronchodilator market due to their rapid and effective bronchodilating activity.
Especially long-acting beta-2 agonists (LABAs), beta-2 agonists have become the mainstay of bronchodilators available. These drugs are very essential in treating both acute and chronic respiratory diseases as they relax airway smooth muscles, therefore producing quick and powerful bronchodilation. Beta-2 agonists' fast start of action, extended duration of impact, and adaptability in treating many respiratory diseases—including asthma and COPD—help to explain their appeal.
Moreover, the therapeutic potential and commercial presence of combination treatments including LABAs with inhaled corticosteroids have been much improved.
North America dominates the bronchodilator market, owing to a high frequency of respiratory illnesses and modern healthcare infrastructure.
With the biggest market share, North America dominates the worldwide bronchodilators market. The great frequency of respiratory disorders, especially asthma and COPD, in nations such as the United States and Canada explains much of this regional dominance. The Centers for Disease Control and Prevention (CDC) estimate that 16 million individuals suffer with COPD whereas 25 million Americans have asthma. Further driving market expansion in the area are its sophisticated healthcare system, heavy healthcare spending, and advantageous reimbursement rules. Furthermore supporting market growth in respiratory medicine are the existence of big pharmaceutical corporations and continuous research and development projects.
Strong regulations that allow innovative bronchodilator treatments to be quickly approved and commercialized also help the area. Moreover, rising awareness of respiratory health combined with an aging population prone to chronic respiratory diseases keeps demand for bronchodilators in North America under constant flux.
Strong rivalry among both established pharmaceutical corporations and new entrants defines the bronchodilators industry. Important players in the market are emphasizing research and development in order to launch creative ideas and expand their range of goods. Common tactics used to improve market situations include strategic alliances, mergers and acquisitions, and licencing agreements. To set their products apart, companies are also funding digital health technologies and innovative medication delivery systems.
Combining treatments that provide better effectiveness and patient compliance are becoming more popular on the market. As patents on numerous important bronchodilators expire, generic medicine makers also face growing competition. This competitive scene is inspiring creativity and helping the bronchodilators industry to develop generally.
- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Sunovion Pharmaceuticals Inc.
- Mylan N.V.
- Cipla Ltd.
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. Company Profiles (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. GlaxoSmithKline plc
5.2. AstraZeneca plc
5.3. Boehringer Ingelheim International GmbH
5.4. Novartis AG
5.5. Teva Pharmaceutical Industries Ltd.
5.6. Merck & Co., Inc.
5.7. Sunovion Pharmaceuticals Inc.
5.8. Mylan N.V.
5.9. Cipla Ltd.
5.10. F. Hoffmann-La Roche Ltd.
5.11. Lupin Limited
5.12. Sanofi S.A. (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards combination therapies
6.1.2. Rise of digital inhalers and smart devices
6.1.3. Growing focus on biologics for severe asthma
6.2. Market Drivers
6.2.1. Increasing prevalence of respiratory diseases
6.2.2. Technological advancements in drug delivery systems
6.2.3. Rising geriatric population worldwide
6.3. Market Restraints
6.3.1. Patent expirations and generic competition
6.3.2. Stringent regulatory requirements
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Beta2-agonists
7.1.1. Short-acting beta2-agonists (SABAs)
7.1.2. Long-acting beta2-agonists (LABAs)
7.2. Anticholinergics
7.2.1. Short-acting muscarinic antagonists (SAMAs)
7.2.2. Long-acting muscarinic antagonists (LAMAs)
7.3. Methylxanthines
7.3.1. Theophylline
7.3.2. Aminophylline
8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Oral
8.1.1. Tablets
8.1.2. Capsules
8.1.3. Syrups
8.2. Inhaled
8.2.1. Metered-dose inhalers (MDIs)
8.2.2. Dry powder inhalers (DPIs)
8.2.3. Nebulizers
8.3. Parenteral
8.3.1. Intravenous
8.3.2. Subcutaneous
9. BY INDICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Asthma
9.1.1. Mild Intermittent
9.1.2. Mild Persistent
9.1.3. Moderate Persistent
9.1.4. Severe Persistent
9.2. COPD
9.2.1. Emphysema
9.2.2. Chronic Bronchitis
9.3. Allergic Rhinitis
9.3.1. Seasonal Allergic Rhinitis
9.3.2. Perennial Allergic Rhinitis
10. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospital Pharmacies
10.2. Retail Pharmacies
10.3. Online Pharmacies
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. North America
11.1.1. United States
11.1.2. Canada
11.1.3. Mexico
11.2. South America
11.2.1. Brazil
11.2.2. Argentina
11.2.3. Rest of South America
11.3. Europe
11.3.1. Germany
11.3.2. United Kingdom
11.3.3. France
11.3.4. Italy
11.3.5. Spain
11.3.6. Russia
11.3.7. Rest of Europe
11.4. Asia-Pacific
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia
11.4.5. South Korea
11.4.6. Rest of Asia-Pacific
11.5. Middle-East
11.5.1. UAE
11.5.2. Saudi Arabia
11.5.3. Turkey
11.5.4. Rest of Middle East
11.6. Africa
11.6.1. South Africa
11.6.2. Egypt
11.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
BY DRUG CLASS
BY ROUTE OF ADMINISTRATION
BY INDICATION
BY DISTRIBUTION CHANNEL
BY REGION
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
